TTRX — Turn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023016 ·
Last close
$8.55
Market Cap
$261.40M
52W High
$16.45
52W Low
$2.57
ADV30
99,462
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -1,984,442 | -6,230,868 | 16,349,722 | 10,363,975 | 10,657,545 |
| Jun 2026 | 0 | — | -1,628,060 | -5,849,734 | 16,960,719 | 10,288,510 | 16,273,831 |
| Mar 2026 | 0 | — | -1,246,143 | -970,972 | 18,644,136 | 11,217,671 | 12,526,588 |
| Dec 2025 | 0 | — | -2,193,570 | 279,070 | 12,162,241 | 5,076,144 | 7,475,518 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,281,841
Investing CF
$-65,606
Financing CF
$12,605,266
CapEx
$-65,606
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.50
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-35,441,826
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-10,957,433
Pretax Income TTM
$-12,772,504
Interest Exp TTM
$582,567
Analysts
2
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,858,648 | -3,194,080 | 12,162,241 | 7,475,518 | 4,686,723 | -2,562,901 |
| Dec 2024 | 0 | -1,797,124 | -1,768,415 | 2,048,889 | 2,226,321 | -177,432 | -1,361,305 |
| Dec 2023 | 0 | -2,308,149 | -2,292,267 | 2,013,560 | 1,927,792 | 85,768 | -1,377,680 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$16,960,719
Forward EPS
$-0.15
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $8.89 · call volume: 1 · put volume: 6Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | $258.24M | $8.63 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $253.10M | $8.69 | — |
| CAMP | Camp4 Therapeutics Corp | $251.02M | $4.00 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $250.73M | $0.15 | — |
| GLSI | Greenwich LifeSciences, Inc. | $274.48M | $18.70 | — |
News headlines (Yahoo Finance, 1h cache)
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
2026-11-16 12:00 · Yahoo
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
2026-11-09 12:00 · Yahoo
Turn Therapeutics’ GX-03 Earns "Developmental Immunology Solution of the Year" in 2026 BioTech Breakthrough Awards Program
2026-11-05 13:00 · Yahoo
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
2026-10-21 20:01 · Yahoo
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
2026-10-21 13:00 · Yahoo
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
2026-09-09 12:00 · Yahoo
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
2026-08-12 20:30 · Yahoo
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
2026-07-11 17:02 · Yahoo
Turn Therapeutics’ stock jumps on AD data and trial expansion
2026-07-08 11:17 · Yahoo
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
2026-07-07 12:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.